Literature DB >> 3235666

Characteristics of anti-Legionella antibodies in patients infected with Legionella pneumophila serogroups 1, 6, and 10.

T L van Zwet1, P L Meenhorst, P C Leijh, M R Daha, R van Furth.   

Abstract

Nosocomial infections with Legionella pneumophila serogroups 1 and 10 in the Leiden University Hospital and infections with L. pneumophila serogroup 6 in neighboring hospitals gave us an opportunity to study the development of opsonizing antibodies against L. pneumophila serogroups 1, 6, and 10 in the serum of 13 patients. Seven of these patients were infected with L. pneumophila serogroup 1, two were infected with serogroup 6, and four were infected with serogroup 10. The opsonic cross-reactivity of antibodies against these serogroups of L. pneumophila and complement involvement in opsonization were also investigated. Convalescent-phase sera from patients infected with L. pneumophila serogroup 1 or 6 were able to promote ingestion of these serogroups by polymorphonuclear leukocytes, whereas ingestion of L. pneumophila serogroup 10 was enhanced only in the presence of convalescent-phase sera from patients infected with this serogroup. Opsonization of L. pneumophila serogroups 1, 6, and 10 was complement dependent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3235666      PMCID: PMC266896          DOI: 10.1128/jcm.26.11.2377-2381.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Serospecificity and opsonic activity of antisera to Legionella pneumophila.

Authors:  W Johnson; E Pesanti; J Elliott
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Measure of immunoglobulin G-, M-, and A-specific titers against Legionella pneumophila and inhibition of titers against nonspecific, gram-negative bacterial antigens in the indirect immunofluorescence test for legionellosis.

Authors:  H W Wilkinson; C E Farshy; B J Fikes; D D Cruce; L P Yealy
Journal:  J Clin Microbiol       Date:  1979-11       Impact factor: 5.948

3.  The glomerular permeability determined by dextran clearance using Sephadex gel filtration.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1968       Impact factor: 1.713

4.  Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages.

Authors:  M R Daha; L A Van Es
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

5.  Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes.

Authors:  P C Leijh; M T van den Barselaar; T L van Zwet; M R Daha; R van Furth
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

6.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

7.  Indirect immunofluorescence test for serodiagnosis of Legionnaires disease: evidence for serogroup diversity of Legionnaires disease bacterial antigens and for multiple specificity of human antibodies.

Authors:  H W Wilkinson; B J Fikes; D D Cruce
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

8.  Interaction of the Legionnaires' disease bacterium (Legionella pneumophila) with human phagocytes. I. L. pneumophila resists killing by polymorphonuclear leukocytes, antibody, and complement.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

9.  Legionella pneumophila serogroup 12 isolated from human and environmental sources.

Authors:  W L Thacker; H W Wilkinson; R F Benson; D J Brenner
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

10.  Interaction of the legionnaires' disease bacterium (Legionella pneumophila) with human phagocytes. II. Antibody promotes binding of L. pneumophila to monocytes but does not inhibit intracellular multiplication.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.